• Nektar Therapeutics recently reported new 52-week maintenance data for its immune-modulating drug rezpegaldesleukin in atopic dermatitis and shared additional Phase 2b results in alopecia areata, both supported by FDA Fast Track designations.
• The company also granted stock options and restricted stock units to six newly hired employees under its 2025 Inducement Plan, underscoring its efforts to attract talent as it advances late-stage clinical programs.
• Next, we’ll examine how the latest Fast Track-supported rezpegaldesleukin data may influence Nektar’s investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Nektar Therapeutics Investment Narrative Recap

To own Nektar Therapeutics, you need to believe rezpegaldesleukin can translate its Phase 2b signals and Fast Track status into a successful Phase 3 program in atopic dermatitis, while the company continues to fund operations as a pre-commercial, loss-making biotech. The latest 52 week maintenance data and additional alopecia areata results appear supportive of the near term Phase 3 ZENITH AD catalyst, but do not remove the core risks around cash burn, dilution, and clinical execution.

Among recent announcements, the strengthened rezpegaldesleukin dataset in atopic dermatitis stands out as most relevant, since Nektar plans to move into Phase 3 ZENITH AD in 2026. These longer term maintenance results, together with Fast Track designation, feed directly into how investors might weigh the upside of a successful late stage readout against ongoing net losses of US$164.1 million in 2025 and repeated equity raises to sustain the program.

Yet, while the new data help the story, investors should be aware that ongoing dilution and concentrated dependence on rezpegaldesleukin still leave...

Nektar Therapeutics’ narrative projects $46.8 million revenue and $9.1 million earnings by 2029. This implies revenues will decline by 5.4% per year and requires a $173.2 million earnings increase from -$164.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $144.25 fair value, a 66% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to rise about 32 percent annually and earnings to swing toward US$25.5 million by 2029, so this new rezpegaldesleukin data could either reinforce that upbeat view or force a rethink if it challenges the idea that Phase 3 results will fully support such ambitious targets.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth as much as 90% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.